share_log

Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $8

Benzinga ·  Oct 24, 2023 08:20

Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $15 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment